中文简体
中文繁体
English
ABOUT IASO
Company Overview
Management Team
Scientific Advisory Board
Partnership
SCIENCE & PRODUCTS
Pipeline
Technology Platforms
Manufacturing
Publictaions
Expanded Access
NEWS
Press Release
Media Report
CAREERS
Working at IASO
Opportunities
CONTACT
NEWS
Press Release
Media Report
Search
21/08
2026
IASO Bio's Registration Application for FUCASO® (equecabtagene autoleucel) Accepted by Australia's TGA
30/07
2026
Umoja Biopharma announces United States clinical trial initiation of industry’s first known CD22-targeted In Vivo CAR-T Therapy, developed in collaboration with IASO Bio
13/08
2026
IASO Biotechnology Announces Acquisition of Singapore-Based Cell Therapy Company MediSix Therapeutics
18
2026-06
IASO Bio Announces NDA Approval of Equecabtagene Autoleucel by the Singapore Health Sciences Authority (HSA) for the Treatment of Relapsed or Refractory Multiple Myeloma, Marking a Key Milestone in International Commercialization
10
2026-04
IASO Bio Establishes International Partnership with Instituto Butantan to Develop Innovative Therapy for Hematological Cancer
24
2026-03
IASO Bio Has Received Clearance from Japan’s PMDA to Initiate Clinical Trial for CAR-T Therapy Equecabtagene Autoleucel in Second- or Third-Line Multiple Myeloma
08
2025-12
IASO Bio Presents Updated Results for Equecabtagene Autoleucel in High-Risk Newly Diagnosed Multiple Myeloma Patients at 2025 ASH
27
2025-11
IASO Bio Announces BLA Approval of Fucaso (Equecabtagene Autoleucel) by the Hong Kong Department of Health for the Treatment of Relapsed or Refractory Multiple Myeloma
29
2025-10
IASO Bio Partners with Korea's GC Cell to Bring CAR-T Therapy to Korea
22
2025-10
Blood Publishes Promising Results of IASO Bio's Anti-GPRC5D CAR-T RD118 in Relapsed/Refractory Multiple Myeloma
<
1
2
3
4
5
>
